Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth Files for IPO of American Depositary Shares

NEW YORK – Precision diagnostics company MDxHealth said on Wednesday that it has confidentially submitted a draft registration statement to the US Securities and Exchange Commission relating to a proposed initial public offering of American depositary shares in the US.

The company, which has headquarters in Herstal, Belgium, and Irvine, California, did not specify the number of ADSs it plans to offer, nor the timing or price for the proposed offering, but said it expects the public offering to take place after the SEC completes its review process.

In its recent earnings report for the first half of 2021, MDxHealth said its revenues increased 9 percent year over year, thanks largely to healthy increases in sales of its prostate cancer tests, SelectMDx and ConfirmMDx.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.